This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Sylvie Monferran
PhD
About me
- Associate professor at Stromalab Institute, Toulouse, France since 2019
- Associate professor at the Stromalab Institute, Toulouse, France from 2019 to 2020
- Associate professor at Cancer Research Center, Toulouse, France from 2011 to 2019
- Associate professor at Cancer Research Center, Marseille, France from 2007 to 2011
- Post doctoral fellow at Institut Claudius Regaud, Toulouse center for cancer research, France, from 2003 to 2007
- PhD student at IPBS laboratory, Toulouse, France from 1999 to 2003
Research interests
My research interests focus on two main areas: cell invasion and tumor resistance to standard anticancerous therapies. In several tumor cell lines (leukemia, glioblastoma, cancer stem cells) and preclinical models, I have deciphered the signaling pathways involved in these two processes, focusing on the role of integrins and RhoGTPases. I have shown that some of these molecular actors are involved in invasion and resistance processes and can activate them, giving a selective advantage to tumor cells. More recently, I joined the Stromalab to become interested in adipose stromal cell migration. There, I study more specifically the fascinating ability of adipose stromal cells to migrate notably during muscle regeneration.
Teaching activity
Molecular biology, cell biology and oncology at the Faculty of Pharmaceutical Sciences (Toulouse III University), from the first year common to health studies (PACES/PASS/LAS) to Master
Scientific affiliations
Editor for International Journal of Molecular Sciences
Publications / Patents
Patent: EP18305148.1. WO2019158512 Toulas C, Moyal E, Monferran S. Methods for the prognosis and the treatment of glioblastoma.
Mouly L, Gilhodes J, Lemarié A, Cohen-Jonathan Moyal E, Toulas C, Favre G, Sordet O, Monferran S. (2019) The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis. Int J Mol Sci 20(15).
Mouly L, Mamouni K, Gence R, Cristini A, Cherier J, Castinel A, Legrand M, Favre G, Sordet O, Monferran S. (2018) PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin. Cell Death Disease. 12;9(9):931.
Boyrie S, Delmas C, Lemarié A, Lubrano V, Dahan P, Malric L, Luis J, Gilhodes J, Tosolini M, Mouly L, Lehmann M, Toulas C, Cohen-Jonathan Moyal E, Monferran S. (2018) RND1 regulates migration of human glioblastoma stem-like cells according to their anatomical localization and defines a prognostic signature in glioblastoma. Oncotarget. 9(73):33788-33803.
Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Ferreira Da Mota D, Gilhodes J, Filleron T, Siegfried A, M. Evrard S, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A. (2018) Inhibiting Integrin β8 to differentiate and radiosensitize Glioblastoma-Initiating cells. Molecular Cancer Research. 17(2):384-397.
Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A. (2017) Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. Oncotarget. 8(49):86947-86968.